PharmacyCodes



Methyldiazepinone, Pharmaceutical en es it fr

Methyldiazepinone, Pharmaceutical Brand names, Methyldiazepinone, Pharmaceutical Analogs

Methyldiazepinone, Pharmaceutical Brand Names Mixture

  • No information avaliable

Methyldiazepinone, Pharmaceutical Chemical_Formula

C16H13ClN2O

Methyldiazepinone, Pharmaceutical RX_link

http://www.rxlist.com/cgi/generic/diazepam.htm

Methyldiazepinone, Pharmaceutical fda sheet

Methyldiazepinone, Pharmaceutical msds (material safety sheet)

Methyldiazepinone,_Pharmaceutical MSDS

Methyldiazepinone, Pharmaceutical Synthesis Reference

Reeder, Sternbach; U.S. Pat. 3,371,085 (1968)

Methyldiazepinone, Pharmaceutical Molecular Weight

284.74 g/mol

Methyldiazepinone, Pharmaceutical Melting Point

125-126oC

Methyldiazepinone, Pharmaceutical H2O Solubility

Slightly soluble (50 mg/L)

Methyldiazepinone, Pharmaceutical State

solid

Methyldiazepinone, Pharmaceutical LogP

2.988

Methyldiazepinone, Pharmaceutical Dosage Forms

Tablets; Injectable solution

Methyldiazepinone, Pharmaceutical Indication

Used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome.

Methyldiazepinone, Pharmaceutical Pharmacology

Diazepam, a benzodiazepine, generates the same active metabolite as chlordiazepoxide and clorazepate. In animals, diazepam appears to act on parts of the limbic system, the thalamus and hypothalamus, and induces calming effects. Diazepam, unlike chlorpromazine and reserpine, has no demonstrable peripheral autonomic blocking action, nor does it produce extrapyramidal side effects; however, animals treated with diazepam do have a transient ataxia at higher doses. Diazepam was found to have transient cardiovascular depressor effects in dogs. Long-term experiments in rats revealed no disturbances of endocrine function. Injections into animals have produced localized irritation of tissue surrounding injection sites and some thickening of veins after intravenous use.

Methyldiazepinone, Pharmaceutical Absorption

Essentially complete, with a bioavailability of 93%.

Methyldiazepinone, Pharmaceutical side effects and Toxicity

Symptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored.

Methyldiazepinone, Pharmaceutical Patient Information

Methyldiazepinone, Pharmaceutical Organisms Affected

Humans and other mammals